Nuveen’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Nuveen’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292K	Buy	95,264 +18,592	+24%	+$57K	﹤0.01%	3014
2025 Q4	$273K	Hold	76,672	–	–	﹤0.01%	3067
2025 Q3	$268K	Hold	76,672	–	–	﹤0.01%	3087
2025 Q2	$157K	Buy	+76,672	New	+$192K	﹤0.01%	3201
2023 Q2	–	Sell	-52,343	Closed	-$497K	–	3291
2023 Q1	$497K	Hold	52,343	–	–	﹤0.01%	2804
2022 Q4	$497K	Buy	52,343 +3,537	+7%	+$9.93K	﹤0.01%	2885
2022 Q3	$464K	Buy	48,806 +22,337	+84%	+$131K	﹤0.01%	2972
2022 Q2	$251K	Buy	+26,469	New	+$193K	﹤0.01%	3126

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen's STLN Position: Q1 2026 in Review

Nuveen increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 24% in Q1 2026, buying an estimated $57K and bringing the position to 95,264 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #3014.

Nuveen first reported a position in STLN in Q2 2022 and has held it in 8 quarters since. The position peaked at $497K in Q1 2023. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Nuveen held 95,264 shares of Starling Oncology Institute, Inc. Common Stock worth $292K as of Q1 2026.
Nuveen bought 18,592 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $57K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3014 holding.
Nuveen first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 8 quarters since.
Nuveen's Starling Oncology Institute, Inc. Common Stock position peaked at $497K in Q1 2023.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.